Qurient Decides on 10.9 Billion KRW Capital Increase for German Joint Venture
On December 19, Qurient announced that it has decided to carry out a third-party paid-in capital increase of 6.26 million euros (approximately 10.9 billion KRW) for 'QLi5 Therapeutics,' a joint venture established with the Max Planck Institute in Germany and the Lead Discovery Center. With this investment, Qurient's stake in QLi5 will increase from approximately 58% to about 64%.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Treatments Available as Outbreak Accelerates... '105 Dead' and Fear Grows as American Infected"
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Mother of Three Gang-Raped on Bus in India... Outrage as Bus Driver Implicated
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
